ALKERMES | Betriebsaufwand



Operating Expenses Veränderung Datum
AbbVie USD 16.59B 5.96B 2024-12
Acadia Pharmaceuticals USD 106.1M 112.66M 2024-12
ALKERMES USD 267.3M 6.09M 2024-12
Amgen USD 6.78B 401M 2024-12
Biogen USD 2.01B 13.3M 2024-12
BioMarin Pharmaceutical USD 585.91M 45.94M 2024-12
Bristol-Myers Squibb USD 11.55B 1.84B 2024-12
Eli Lilly USD 8.38B 1.53B 2024-12
Gilead Sciences USD 5.12B 1.54B 2024-12
Intra Cellular Therapies USD 228.42M 14.2M 2024-12
Ionis Pharmaceuticals USD 337.4M 54.93M 2024-12
J&J USD 18.63B 500M 2024-12
Malin Corporation EUR 700K 1.6M 2024-06
Merck USD 11.33B 1.4B 2024-12
Neurocrine Biosciences USD 485.7M 47.4M 2024-12
Otsuka Holdings JPY 537.27B 50.89B 2024-12
Pfizer USD 18.17B 5.63B 2024-12
Regeneron Pharmaceuticals USD 2.8B 26.53B 2024-12
Vertex Pharmaceuticals USD 1.89B 230.4M 2024-12



ALKERMES Betriebsaufwand - Diese Werte, historische Daten, Prognosen, Statistiken, Diagramme und ökonomische Kalender - Mar 2025.